Drug intelligence / Profile preview

ZK2505

Development stage: Preclinical
Lead developer: Lee's Pharmaceutical

Overview

ZK2505 is a preclinical-stage oncology drug candidate being developed by Lee's Pharmaceutical. It is currently under investigation for the treatment of solid tumors. As of current public pipeline disclosures, the specific molecular target, mechanism of action, and modality of ZK2505 remain proprietary and have not been released, though it is categorized within the company's oncology research portfolio. The drug is undergoing early-stage studies to determine its potential efficacy and safety profile in cancer models.

Other names: ZK2505ZK-2505ZK 2505

Beyond the preview

Go deeper on ZK2505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZK2505.

Explore the full profile